The Centers for Disease Control and Prevention (CDC) said COVID-19 vaccine uptake among children 5 to 11 years old in the United States remained low during the first 11 weeks of vaccine eligibility, especially in high social vulnerability index (SVI) areas. The research was published today in Morbidity and Mortality Weekly Report (MMWR).
World Health Organization (WHO) flu vaccine strain selection advisors met this week to recommend the strains to include for the Northern Hemisphere's 2022-2023 flu season, swapping out the components for the H3N2 and influenza B Victoria lineage strains.
Mortality rates among children born with congenital Zika syndrome up to 3 years of age were more than 11 times higher than those without Zika, researchers reported today in the New England Journal of Medicine.
A large multistate cohort study of more than 40,000 pregnant women and their nonpregnant peers found no link between COVID-19 vaccination during pregnancy and preterm or small-for-gestational-age births.
United States flu activity jumped again the week ending Dec 18, with eight states reporting high or very high activity and the first two pediatric flu deaths reported for the season, the US Centers for Disease Control and Prevention (CDC) said today in its regular update.
A new study presented at an American Society of Health-System Pharmacists (ASHP) meeting finds that influenza vaccination rates are low for people without a regular healthcare provider, at just 20.5%, as well as among minority groups.
Vaccine coverage among American adults with a regular provider was 44.5%, according to the research, which was presented yesterday at the society's midyear conference.
A UK study yesterday in The Lancet finds that flu and COVID-19 vaccines can be safely co-administered.
Use of a rapid diagnostic test in patients with bloodstream infections (BSIs) was associated with shorter times to optimal antibiotic therapy and antibiotic de-escalation, researchers reported yesterday in Clinical Infectious Diseases.
Hospitalized COVID-19 patients who were treated with remdesivir within 2 days of admission had lower mortality rates than their matched cohort, according to a study today in Clinical Infectious Diseases. The observational cohort consisted of US adults hospitalized with COVID-19 from August to November 2020; 28,855 received remdesivir and 16,887 did not.
The 10-year plan starts today and gives recommendations for a range of scientific disciplines to better address seasonal flu and prepare for the next flu pandemic.
